LPC
CUE icon

Lion Point Capital’s Cue Biopharma CUE Stock Holding History

Lion Point Capital’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.67M Sell
52,928
-20,500
-28% -$463K 7.99% 1
2026
Q1 		$506K Hold
73,428
– – 3.03% 12
2025
Q4 		$673K Buy
+73,428
New +$1.35M 3.48% 11

Other funds holding CUE

BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return

Lion Point Capital's CUE Position: Q2 2026 in Review

Lion Point Capital reduced its Cue Biopharma (CUE) stake by 28% in Q2 2026, selling an estimated $463K and leaving 52,928 shares worth $1.67M. The position accounts for 7.99% of the portfolio, ranked #1.

Lion Point Capital first reported a position in CUE in Q4 2025 and has held it in 3 quarters since. 49 funds tracked by Wall St. Rank hold CUE as of Q2 2026.

  • Lion Point Capital held 52,928 shares of Cue Biopharma worth $1.67M as of Q2 2026.
  • Lion Point Capital sold 20,500 Cue Biopharma shares in Q2 2026, an estimated $463K.
  • Cue Biopharma made up 7.99% of Lion Point Capital's portfolio in Q2 2026, its #1 holding.
  • Lion Point Capital first reported a position in Cue Biopharma in Q4 2025 and has held it in 3 quarters since.
  • 49 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2026.

Based on Lion Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.